Resistance to thyroid hormones comprises a group of rare conditions characterized by reduced tissue sensitivity to the biological action of thyroxine (T4) and triiodothyronine (T3), resulting in uncoupling between peripheral signaling and central regulation of the hypothalamic-pituitary-thyroid axis. In clinical practice, suspicion typically arises from a “discordant” biochemical profile, in which thyroid hormone levels are elevated or inappropriately distributed relative to a nonsuppressed thyroid-stimulating hormone (TSH) concentration, or from multisystem clinical phenotypes that cannot be explained by the traditional categories of hyperthyroidism or hypothyroidism. In its modern sense, the term includes forms caused by defects in nuclear receptors, namely thyroid hormone receptor beta (TRβ) and thyroid hormone receptor alpha (TRα), as well as a broader spectrum of genetic disorders that impair the cellular transport or intracellular metabolism of thyroid hormones, producing functional “insensitivity” in specific compartments of the body.
The clinical importance of diagnosis is substantial because misinterpretation of the condition may lead to unnecessary or potentially harmful interventions, such as antithyroid therapy, ablation, or thyroidectomy, when the underlying problem is not primary excessive hormone production but an alteration in the biological response. Management therefore requires a structured endocrinological approach that integrates family history, organ-specific manifestations, the dynamics of hormonal testing, and genetic confirmation when indicated.
Resistance to thyroid hormones is rare overall, and its true epidemiology is probably underestimated because many cases remain unrecognized or are classified as laboratory abnormalities, atypical hyperthyroidism, or unrecognized thyroid dysfunction. The best-known and historically described form is resistance mediated by the beta receptor, commonly referred to as resistance to thyroid hormone beta, which accounts for a substantial proportion of inherited disorders of thyroid hormone action. In recent years, however, the increased availability of genetic testing and the formalization of diagnostic frameworks for biochemical “discordance” have led to the identification of forms associated with alpha receptor mutations, transporter defects, and metabolic disorders, broadening the epidemiological spectrum and increasing their recognition in specialist centers.
The main clinical risk factor is a persistent biochemical profile of elevated thyroid hormones with nonsuppressed TSH, repeatedly documented over time and confirmed using appropriate analytical methods. A suggestive family history is also common because many forms are inherited and may follow an autosomal dominant pattern with broad penetrance and phenotypic variability. In these families, the presence of individuals with goiter development, neurodevelopmental disorders, unexplained tachycardia, attention difficulties, or atypical growth patterns becomes an intrinsic epidemiological feature that may guide the clinical investigation even before molecular confirmation.
A high-risk setting is represented by patients evaluated for hyperthyroidism that is inconsistent with the expected clinical manifestations or refractory to conventional treatment. Resistance may be suspected when a patient has elevated free thyroxine (FT4) and free triiodothyronine (FT3) levels without TSH suppression and peripheral manifestations that are not uniformly compatible with thyrotoxicosis, or when therapeutic interventions aimed at reducing thyroid hormone production worsen certain manifestations and fail to normalize pituitary regulation. Conversely, the recognition of a phenotype suggestive of tissue hypothyroidism despite normal or elevated FT4, as may occur in some TRα-related forms, should raise the possibility of a disorder of hormone responsiveness rather than hormone availability.
Diagnosis is more commonly established during childhood or young adulthood because of goiter development, growth disorders, behavioral abnormalities, or the incidental detection of abnormal thyroid tests during screening. However, phenotypic variability is such that a substantial proportion of individuals first present during adulthood, sometimes after years of being labeled as having subclinical thyrotoxicosis, central hyperthyroidism, or analytical abnormalities. In this setting, observed epidemiology is strongly influenced by the healthcare system’s ability to recognize the pattern and refer the patient for specialist endocrinological evaluation.
There are also factors that increase the risk of delayed or incorrect diagnosis. These include the use of medications that alter binding proteins or peripheral hormone conversion, systemic conditions that modify thyroid parameters, and, most importantly, analytical interference in immunometric assays, which may mimic or conceal the characteristic discordance. The apparent epidemiology of the disorder is therefore closely linked to laboratory quality and to the endocrinologist’s methodological approach to verifying the reproducibility of the findings.
In terms of clinical risk, the most relevant adverse outcomes arise not so much from the rarity of the condition as from its potential to be confused with more common disorders. The principal epidemiological determinant of morbidity is therefore the likelihood of inappropriate treatment or inadequate management of organ-specific manifestations, particularly cardiovascular and neuropsychiatric manifestations, in individuals who might otherwise maintain a good quality of life with targeted and individualized interventions.
The action of thyroid hormones depends on an integrated physiological chain that includes the circulating availability of T4 and T3, their transport into tissues, the intracellular conversion of T4 into T3 by deiodinases, and their interaction with the nuclear thyroid hormone receptors TRα and TRβ, which regulate hormone-dependent gene transcription. Resistance may arise at any point along this chain, producing a mismatch between the hormone concentration measured in the blood and the actual biological response within tissues. Consequently, resistance does not always correspond to a single receptor defect but may result from a range of mechanisms that reduce the effectiveness of thyroid hormone signaling at the cellular and organ levels.
In forms caused by a beta receptor defect, the most common etiology is the presence of pathogenic variants in the gene encoding TRβ, frequently acting through a dominant-negative mechanism. The mutated receptor may bind abnormally to deoxyribonucleic acid (DNA) and transcriptional cofactors and, by competing with the normal receptor, attenuate the transcriptional response to T3. Because TRβ is highly expressed in the pituitary and hypothalamus, reduced sensitivity of central feedback requires higher concentrations of T4 and T3 to achieve the same suppression of TSH. This produces a biochemical pattern in which TSH remains inappropriately normal or elevated despite high thyroid hormone levels, with persistent trophic stimulation of the thyroid and a tendency toward goiter and compensatory hormone overproduction.
The pathophysiology is nevertheless intrinsically heterogeneous because the distribution of thyroid hormone receptors and activating mechanisms is not uniform across tissues. Some organs may be relatively protected from the excess of circulating hormones, whereas others may retain greater sensitivity and therefore develop manifestations of tissue hyperthyroidism in the presence of elevated T3 levels. This explains the often paradoxical clinical combination of tachycardia or adrenergic hyperreactivity with manifestations that are not consistent with overt thyrotoxicosis, as well as the frequent absence of significant weight loss or marked heat intolerance in many patients.
In forms caused by an alpha receptor defect, the biochemical pattern may differ because TRα is particularly important in the heart, bone, skeletal muscle, and nervous system. The primary problem is not pituitary feedback but reduced peripheral hormone action, producing phenotypes that may resemble tissue hypothyroidism and present with slowing, constipation, impaired growth and development, and skeletal abnormalities. In some cases, biochemical testing shows a reduced T4:T3 ratio or a relatively elevated T3 concentration compared with T4, reflecting compensatory metabolic adaptations and variability in intracellular hormone metabolism. Pathogenesis therefore results in a distribution of impaired responsiveness that differs from that observed in TRβ-related forms and requires a specific pathophysiological interpretation centered on the organs in which the alpha receptor predominates.
Another category involves defects in the transport of thyroid hormones across the cell membrane. In some tissues, the entry of T4 and T3 depends on specific transporters, and a defect may cause a local deficiency of thyroid hormone signaling despite elevated circulating concentrations. The clinical paradigm is represented by transporter defects associated with a severe neurological phenotype, in which the brain, which is particularly dependent on specific transport mechanisms, develops functional hypothyroidism with neuromotor consequences, while other compartments may be exposed to hormone excess. This dissociation between compartments produces a mosaic pathophysiology and explains why treatment requires strategies directed at tissue bioavailability rather than simply normalizing plasma concentrations.
Finally, defects in intracellular metabolism, including those that reduce the ability to generate active T3 from T4 or alter the balance between hormone inactivation and activation, are included within the spectrum of conditions characterized by reduced sensitivity. In these disorders, apparently adequate circulating hormone concentrations fail to produce an effective intracellular signal, or abnormal metabolite production shifts the regulatory balance differently across tissues. The clinical consequence is a complex syndrome that may involve growth, development, lipid metabolism, and cardiovascular function, with an abnormal but not uniform laboratory profile that requires an integrated endocrine and metabolic interpretation.
In summary, resistance to thyroid hormones is the pathophysiological result of a failure in thyroid hormone signal transduction and feedback regulation of the axis. The common feature is the body’s need to increase thyroid hormone concentrations to achieve an adequate response in certain compartments, with the risk that other, less resistant compartments are exposed to a relative excess. This asymmetry is responsible for the clinical heterogeneity, diagnostic difficulties, and inability to define management solely according to numerical laboratory targets.
The clinical manifestations of resistance to thyroid hormones are extremely variable and depend on the underlying molecular defect, the pattern of receptor and transporter expression in tissues, and the extent to which compensatory mechanisms can stabilize homeostasis. A recurrent feature is the absence of a pure syndrome of hyperthyroidism or hypothyroidism, with a mixed presentation in which some organs show signs of adrenergic excess and others show functional thyroid hormone signaling deficiency. Clinical assessment must therefore reconstruct the timing of symptoms accurately, distinguishing stable long-term manifestations from periods of decompensation associated with physiological changes, pregnancy, puberty, comorbidities, or inappropriate therapeutic interventions.
In the medical history of TRβ-related forms, patients may report palpitations, reduced exercise tolerance, fine tremor, or anxiety, although their severity is often disproportionate to FT4 and FT3 concentrations. Goiter development and a sensation of neck fullness are common, as are attention difficulties, hyperactivity, or mood instability, particularly during childhood and adolescence. In some individuals, the presentation is almost exclusively biochemical, with no significant symptoms and diagnosis following testing performed for unrelated reasons. In others, the neurobehavioral component becomes predominant and is associated with inconsistent school performance, sleep disturbances, and irritability. These manifestations may be incorrectly interpreted as primarily psychiatric unless the endocrine findings are considered.
On physical examination, goiter is a common finding in forms associated with nonsuppressed TSH because the thyroid is exposed to persistent trophic stimulation. Sinus tachycardia, a hyperdynamic circulation, increased pulse pressure, and, in more symptomatic cases, signs of adrenergic hyperactivation may be present. However, examination does not typically reveal the features classically associated with autoimmune thyrotoxicosis, such as orbitopathy, pretibial myxedema, or a specific inflammatory presentation, and the absence of these findings may provide an important clue. Body weight is often stable, and the weight loss typical of hyperthyroidism is not always observed because resistance attenuates some of the catabolic effects in certain tissues.
In TRα-related forms, the clinical picture may be dominated by manifestations resembling tissue hypothyroidism, including constipation, fatigue, relative bradycardia, growth delay, abnormalities of bone growth, and skeletal features. During childhood, neurodevelopmental delay, motor or language difficulties, and growth that does not follow the expected trajectory may occur, with possible disproportion or signs of impaired skeletal maturation. These findings require a comprehensive pediatric assessment because reliance on TSH and FT4 alone may fail to identify the condition correctly. In adults, some forms may present with a slowed phenotype, reduced muscle mass, and exercise intolerance, even though the standard thyroid profile does not indicate classical hypothyroidism.
Transport and metabolic defects may produce even more complex multisystem phenotypes. When the central nervous system is predominantly involved, neurological and neurocognitive symptoms become prominent, whereas peripheral tissues may display signs of relative hormone excess. In other cases, the disorder presents with metabolic dysfunction, lipid or hepatic abnormalities, and cardiovascular vulnerability. Such findings require a comprehensive endocrine and metabolic interpretation because impaired thyroid hormone signaling profoundly affects the regulation of lipids, glucose, vascular tone, and cardiac function.
The degree of phenotypic variability requires the medical history to include possible iatrogenic events and previous therapeutic decisions. A patient with resistance to thyroid hormones may previously have received antithyroid medications or ablative treatment, resulting in iatrogenic hypothyroidism and the need for high replacement doses to maintain functional balance. In these cases, the entire clinical course must be reconstructed because the current presentation may reflect both the underlying disorder and the consequences of interventions that permanently altered thyroid physiology.
Resistance to thyroid hormones should be suspected primarily in the presence of a persistent discordance between thyroid hormone levels and TSH, particularly when FT4 and often FT3 are elevated or near the upper limit of normal while TSH remains nonsuppressed. When reproduced in repeated samples obtained under clinically stable conditions, this pattern is one of the principal warning signs and requires a structured diagnostic pathway. Suspicion becomes even stronger when the clinical phenotype is inconsistent with classical hyperthyroidism or when manifestations of both excessive and deficient thyroid hormone signaling coexist in different tissues.
A typical scenario is a patient labeled as hyperthyroid despite the absence of TSH suppression and the presence of only mild or atypical clinical manifestations. In these cases, the temptation to intensify therapies that reduce thyroid hormone production must be resisted until the diagnosis has been clarified because resistance may be worsened by reducing hormone availability to tissues that are already poorly sensitive. The disorder should also be considered when repeated tests show inconsistent fluctuations, when biochemical normalization cannot be achieved with reasonable treatment regimens, or when the clinical course conflicts with the laboratory results.
Suspicion is particularly important when there is a family history of unexplained thyroid abnormalities, goiter development in several relatives, repeated diagnoses of atypical hyperthyroidism, or the use of high doses of levothyroxine without TSH suppression. In many families, diagnosis of the index case allows the identification of other relatives with mild or previously unrecognized phenotypes, improving management and preventing unnecessary interventions. During childhood, the combination of goiter, tachycardia, attention disorders, and a discordant laboratory pattern should prompt early consideration of this diagnosis.
Another scenario involves a patient with suspected thyrotropin-secreting pituitary adenoma (TSHoma) or central hyperthyroidism. Because a thyrotropin-secreting adenoma may also produce elevated thyroid hormone levels with nonsuppressed TSH, resistance must always be included in the differential diagnosis. A pituitary disorder should not be diagnosed without a diagnostic work-up that integrates dynamic testing, peripheral markers, and imaging. A rigorous approach is essential because the therapeutic implications of the two conditions are radically different.
Resistance should also be suspected when the clinical phenotype suggests tissue hypothyroidism but TSH is not elevated and FT4 is not reduced, particularly in the presence of skeletal abnormalities, severe constipation, or developmental disturbances without an alternative explanation. In such cases, TRα-mediated resistance or another disorder of thyroid hormone signaling may provide the correct interpretation, and assessment must include parameters beyond traditional screening tests.
In summary, resistance to thyroid hormones should be suspected when the laboratory and clinical presentation does not fit the classical categories of thyroid dysfunction, when the response to standard therapies is inconsistent, and when the personal or family history suggests an inherited disorder of thyroid hormone action. The practical value of early suspicion is the prevention of iatrogenic harm and the establishment of management based on the organ-specific phenotype rather than biochemical normalization alone.
Diagnosis of resistance to thyroid hormones requires a sequential pathway that begins with confirmation of the biochemical findings and proceeds, when appropriate, to molecular definition of the cause. The first step is to repeat thyroid function testing while carefully considering preanalytical and clinical variables, measuring FT4, FT3, and TSH under stable conditions and collecting information about medications, supplements, and comorbidities that may alter thyroid biochemistry. Because analytical interference may mimic elevated thyroid hormone levels with nonsuppressed TSH, exclusion of assay interference is a decisive step, often achieved by repeating measurements using alternative analytical platforms and conducting targeted investigations in an experienced laboratory.
Once the increase in T4 and T3 has been confirmed as genuine, the next step is to investigate the differential diagnosis of conditions associated with inappropriate TSH secretion. This group includes inherited disorders of thyroid hormone action, TSH-secreting pituitary tumors, and some forms of euthyroid hyperthyroxinemia related to transport proteins. Assessment should include evaluation of clinical consistency and the use of peripheral markers of thyroid hormone action. Parameters such as sex hormone-binding globulin (SHBG), the lipid profile, heart rate, and other metabolic indicators may help determine whether peripheral tissues are being exposed to an excessive or attenuated thyroid hormone signal. However, no individual marker is pathognomonic, and tissue responses may be heterogeneous.
Differentiation between resistance and a TSHoma is a central diagnostic challenge. In addition to clinical and family assessment, dynamic tests and an integrated evaluation of the pituitary axis may be used. The response to thyrotropin-releasing hormone (TRH), when available, and assessment of suppressibility with T3 in selected settings may be helpful, as may pituitary magnetic resonance imaging. Imaging must nevertheless be interpreted cautiously because incidental microadenomas are common and may cause confusion, while resistance may coexist with thyroid nodules or other conditions that distort clinical interpretation. In selected cases, the response to somatostatin analogues may support the diagnosis of a thyrotropin-secreting adenoma but does not replace a comprehensive assessment.
When suspicion of an inherited disorder of thyroid hormone action is strong, testing first-degree relatives for thyroid function abnormalities may provide valuable evidence because the presence of a similar pattern in several family members supports a genetic origin. At this stage, diagnosis may be completed using targeted genetic testing or panels that include the principal genes associated with resistance and related disorders. Identification of a pathogenic TRβ variant supports the diagnosis of resistance to thyroid hormone beta, whereas TRα variants indicate the corresponding phenotype. In cases characterized by an unusual multisystem phenotype or atypical biochemical findings, broader testing of transporter or metabolic genes may be necessary to avoid an incomplete diagnosis.
Assessment does not end with genetic confirmation because a clinically useful diagnosis requires evaluation of complications and target organs. Thyroid volume and possible nodularity should be documented, the cardiovascular system should be assessed with particular attention to rhythm, heart rate, and function, and neurocognitive and behavioral evaluation should be considered in children, adolescents, or patients with specific symptoms. When resistance was previously mistaken for hyperthyroidism and treated, the history of interventions, levothyroxine dosage, and therapeutic targets must be reconstructed because future management depends on the revised pathophysiological interpretation.
When the presentation is acute or the patient is clinically unstable, safety remains the priority. Resistance to thyroid hormones is rarely an emergency in itself, but it may coexist with conditions requiring urgent intervention. The diagnostic work-up must therefore be rigorous but pragmatic, avoiding delays in the presence of significant cardiovascular manifestations and ensuring that every therapeutic decision is consistent with the pathophysiology of the disorder rather than an automatic interpretation of hormone concentrations.
Classification of resistance to thyroid hormones is essential because the term encompasses conditions that differ in mechanism, phenotype, and therapeutic strategy. A fundamental distinction separates forms caused by receptor defects from those caused by transport defects and those caused by defects in intracellular metabolism. This three-part classification reflects the physiological sequence of thyroid hormone action and allows biochemical discordance to be interpreted as the expression of an abnormality downstream from hormone production. Among receptor-related forms, distinguishing TRβ involvement from TRα involvement is crucial because it changes the relative importance of pituitary feedback and the peripheral phenotype.
For TRβ-mediated resistance, it is useful to distinguish a more generalized phenotype, in which both the pituitary and peripheral tissues show reduced sensitivity, from a more pituitary-selective phenotype, in which central feedback is particularly resistant and peripheral tissues remain relatively more sensitive. In clinical practice, this distinction helps explain why some patients show more evident manifestations of excessive peripheral thyroid hormone action despite having nonsuppressed TSH. This remains a conceptual classification that cannot always be rigidly applied to an individual patient because phenotypes may overlap and the response is also influenced by additional genetic variables and the clinical context.
For TRα-mediated resistance, classification is commonly based on the phenotype, including the predominance of tissue hypothyroidism, skeletal involvement, neurodevelopment, and cardiovascular function. In these forms, the biochemical profile may not show the characteristic combination of elevated thyroid hormones and nonsuppressed TSH, making classification more dependent on clinical and genetic integration. Severity is therefore assessed according to the effects on growth, development, and organ function rather than the degree of hormone elevation.
Transport defects that selectively involve the nervous system may be classified as syndromes with marked compartmental dissociation, in which the brain experiences a functional deficiency of thyroid hormone signaling while peripheral tissues may be exposed to a relative excess. Metabolic defects, including those that impair selenoprotein availability and deiodinase function, may be classified according to their biochemical pattern and multisystem phenotype, including associated endocrine manifestations and disorders of growth or neurodevelopment. In these conditions, clinical severity is often determined by the combined effects on several organs and by the availability of targeted treatment.
From a practical perspective, severity in resistance to thyroid hormones is best defined according to clinical impact and organ risk. One patient may have markedly elevated hormone levels but few symptoms, whereas another may develop cardiovascular complications, behavioral disorders, or a large goiter with compressive manifestations. Stratification should therefore include assessment of the heart, thyroid, neurocognitive development, and quality of life, together with the history of previous treatments and the possibility of decompensation during particular physiological states such as pregnancy and puberty.
A clinically useful classification, particularly for management, also considers the status of the thyroid gland: an intact gland with goiter or nodularity, concomitant thyroid disorders such as autoimmunity or structural abnormalities, and iatrogenic conditions following ablative therapy. These factors influence endogenous hormone production, the possible need for replacement therapy, and TSH management, which cannot be interpreted according to conventional algorithms in these patients. Classification is therefore not merely theoretical but provides the basis for an individualized strategy that accounts for both the underlying mechanism and the patient’s anatomical and clinical context.
Treatment of resistance to thyroid hormones is guided by the clinical phenotype and target-organ involvement rather than by the objective of normalizing FT4, FT3, and TSH values. In many patients with TRβ-mediated resistance and minimal symptoms, the principal strategy is to recognize the disorder correctly and avoid therapies that inappropriately reduce thyroid function. This principle is essential because attempting to correct the laboratory values with antithyroid medications or ablative procedures may cause iatrogenic hypothyroidism and increase levothyroxine requirements without achieving physiological TSH suppression or necessarily improving symptoms.
When cardiovascular manifestations are present, particularly tachycardia and palpitations, symptomatic control with beta-blockers can be effective. These agents reduce peripheral adrenergic effects without interfering with the compensatory mechanisms of the axis. This is particularly useful in individuals whose tissues remain relatively sensitive to elevated thyroid hormone concentrations. Medication choice and dosage must be individualized according to the clinical presentation, tolerability, and comorbidities, in a manner similar to the management of adrenergic hyperactivation in other endocrine disorders.
In selected patients with significant goiter, related symptoms, or a need to reduce thyrotropic stimulation, strategies directed at modulating pituitary feedback may be considered. In some settings, thyroid hormone analogues with a stronger effect on central regulation have been used to reduce TSH and thereby decrease its trophic effect on the thyroid. Evidence remains limited, however, and management should take place in experienced centers. Therapeutic decisions must balance potential benefits for goiter and symptoms against the risk of undesirable peripheral effects because tissue sensitivity is heterogeneous.
In TRα-related forms, the therapeutic rationale may differ because the aim is to improve tissue hypothyroidism in organs that depend on the alpha receptor. In these patients, treatment with liothyronine or combinations that increase T3 availability may be considered on an individualized basis, with careful clinical monitoring of growth, cardiac function, development, and gastrointestinal symptoms. Management requires a delicate balance because increasing T3 may improve signaling in resistant tissues while increasing exposure in more sensitive compartments. Treatment must therefore be guided by clear clinical objectives and close follow-up.
In transport or metabolic defects, treatment depends on the mechanism. When thyroid hormone signaling deficiency is compartmentalized, normalizing plasma concentrations does not guarantee clinical benefit and may increase the risk of peripheral excess. In such cases, specific pharmacological strategies or approaches directed at the affected compartment may be considered in highly specialized centers, often within programs dedicated to rare diseases. Supportive treatment nevertheless remains essential and may include rehabilitation, nutritional care, cardiovascular management, and prevention of associated endocrine complications.
The presence of concomitant thyroid disorders, such as autoimmunity or nodular disease with functional autonomy, represents a particularly delicate issue. In these cases, treatment must distinguish manifestations attributable to resistance from those caused by an independent thyroid disorder. Resistance does not exclude the possibility of true nodular or autoimmune hyperthyroidism, but it changes the interpretation of therapeutic targets and the expected response. Management must therefore be individualized and based on a comprehensive assessment, avoiding standardized approaches and prioritizing patient safety.
Follow-up in resistance to thyroid hormones should focus on three objectives: control of symptoms and organ complications, prevention of iatrogenic harm, and periodic reassessment of the thyroid gland and hormonal axis according to the clinical context. Hormone concentrations remain important for documenting the stability of the biochemical pattern and identifying sudden changes suggestive of superimposed conditions, but they cannot be used as the sole measure of treatment adequacy. In particular, persistently elevated FT4 with nonsuppressed TSH may be a stable feature of the disorder and should not automatically lead to treatment escalation when the patient is clinically compensated.
A crucial aspect of monitoring is cardiovascular surveillance, particularly in patients with persistent tachycardia or adrenergic symptoms. Periodic assessment of heart rate, blood pressure, arrhythmias, and exercise tolerance is appropriate, supplemented by electrocardiography (ECG) and echocardiography when indicated. This approach allows the early identification of consequences related to excessive peripheral exposure in sensitive compartments, even when other symptoms are mild.
The thyroid gland should be monitored over time because of the tendency toward goiter and nodularity, particularly in forms associated with persistent thyrotropic stimulation. Periodic ultrasonography, assessment of thyroid volume and compressive manifestations, and evaluation of nodules according to standard diagnostic pathways are appropriate, while recognizing that the endocrine context may influence glandular growth. In patients with a history of inappropriate treatment or an anatomically altered thyroid gland, follow-up should also include reassessment of therapeutic targets and patient education regarding the nature of the disorder because inadequate understanding may lead to autonomous changes in treatment and clinical instability.
During childhood and adolescence, follow-up should include assessment of neurocognitive development and behavior when relevant because resistance is associated with attention disorders and learning difficulties in some families. Collaboration with child neuropsychiatry and psychology may be useful, not to medicalize the behavioral component, but to establish an integrated pathway that considers the endocrine contribution and minimizes the effect on quality of life. In children with suspected TRα-mediated resistance or a phenotype of tissue hypothyroidism, assessment of growth and skeletal maturation becomes a central component of monitoring.
Genetic reassessment and family counseling are part of follow-up when a molecular diagnosis has been confirmed. Informing relatives, discussing reproductive implications, and identifying individuals at risk allow earlier management and reduce the likelihood of inappropriate interventions. In addition, the increasing availability of therapeutic options and programs dedicated to rare diseases makes periodic updating of the care pathway useful, particularly for transport and metabolic disorders in which clinical research is more dynamic.
Finally, follow-up should account for specific physiological stages such as pregnancy, puberty, and aging. During these periods, metabolic requirements, heart rate, thyroid size, and tolerance of symptomatic treatments may change. Planned and individualized monitoring reduces the risk of decompensation and allows management to be adapted while maintaining the principal objective of clinical stability and complication prevention.
The prognosis of resistance to thyroid hormones is generally favorable when the diagnosis is correct and management is directed toward symptoms and target-organ involvement. Many patients lead normal lives and do not require specific interventions on thyroid function, provided that iatrogenic harm is avoided and the most relevant organ manifestations are treated. Phenotypic variability nevertheless means that individual prognosis depends on the type of defect, the severity of cardiovascular and neurocognitive involvement, and the presence of concomitant thyroid disorders or structural complications such as a large goiter.
The most common complication, particularly in forms associated with nonsuppressed TSH, is goiter development with possible progression to nodularity. Although not always clinically significant, it may cause compressive symptoms, require ultrasonographic surveillance, and, in some cases, lead to complex therapeutic decisions. Elevated thyroid hormone concentrations may also predispose to persistent tachycardia and, in susceptible individuals, arrhythmias or chronic hemodynamic effects. Risk is not uniform and depends on residual tissue sensitivity, but it justifies careful cardiovascular monitoring in symptomatic patients.
Another area of potential complications involves neuropsychiatric and neurocognitive function, particularly during childhood and adolescence. Attention disorders, hyperactivity, and learning difficulties may represent a substantial component of the clinical burden and affect social and educational integration. In these situations, functional prognosis improves when the disorder is recognized early and supportive care is integrated, avoiding attribution of the manifestations exclusively to psychological or educational factors without considering the endocrine context.
In TRα-related forms and in transport or metabolic disorders, prognosis depends even more strongly on early diagnosis and the availability of targeted intervention. When the phenotype affects growth, the skeleton, and neurodevelopment, complications may include short stature, bone abnormalities, motor difficulties, and neurocognitive impairment of variable severity. In these cases, prognosis cannot be reduced to an endocrinological assessment but requires a multidisciplinary approach that optimizes development, rehabilitation, and management of comorbidities.
The most preventable and often most clinically relevant complication is iatrogenic harm. Antithyroid treatment, radioiodine therapy, or thyroidectomy performed in the absence of true pathological hormone overproduction may cause iatrogenic hypothyroidism, the need for high replacement doses, and clinical instability. Prevention of this complication depends entirely on the quality of the diagnostic pathway and the clinician’s ability to recognize the characteristic pattern. Patient and healthcare team education therefore has an important influence on prognosis by reducing the risk of therapeutic decisions based on an automatic interpretation of laboratory findings.
Overall, resistance to thyroid hormones is a rare but highly manageable condition when interpreted correctly. Prognosis is generally good but requires thoughtful follow-up of the thyroid, cardiovascular system, and neurobehavioral function, with continuous attention to avoiding inappropriate treatment and selectively addressing the organ manifestations responsible for the true clinical burden of the disorder.